6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

NCT00003997 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: irofulven

Sponsor

National Cancer Institute (NCI)